logo

VERU

Veru·NASDAQ
--
--(--)
--
--(--)

VERU fundamentals

Veru (VERU) expects to report earnings on Dec 17, 2025, with estimated revenue of -- (YoY 0.00%), and EPS at -0.39 (YoY 0.00%).
Revenue estimate / YoY
--
0.00%
EPS estimate / YoY
-0.39
0.00%
Report date
Dec 17, 2025
VERU Earnings Call Summary for Q4,2025
  • Enobosarm Phase IIb Success: 65.4% of patients achieved ≥5% weight loss with 100% lean mass preservation, vs. 47.4% on GLP-1 alone.
  • New Trial Targeting Weight Loss Plateau: PLATEAU trial to evaluate breaking GLP-1 plateaus in ≥65-year-olds, with 72-week weight loss endpoint.
  • Regulatory Flexibility: FDA allows 5% incremental weight loss or physical function improvement as primary endpoints.
  • Financial Strength: $39.2M cash post-offering; R&D spend up 22% to $15.6M.
EPS
Revenue

Revenue & Expenses

Key Indicators

Veru (VERU) key financial stats and ratios, covering profitability, financial health, and leverage.
Veru (VERU)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Veru (VERU)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Veru (VERU)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Veru (VERU) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Veru (VERU) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield